Ken Griffin Caladrius Biosciences, Inc. Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.63 - $1.03 $35,377 - $57,838	-56,154 Reduced 75.68%	18,044 $13,000
Q3 2021 Nov 15, 2021	BUY	$1.15 - $1.57 $35,633 - $48,648	30,986 Added 71.71%	74,198 $91,000
Q1 2021 May 17, 2021	SELL	$1.44 - $2.89 $49,667 - $99,678	-34,491 Reduced 44.39%	43,212 $83,000
Q4 2020 Feb 16, 2021	BUY	$1.39 - $1.87 $29,376 - $39,520	21,134 Added 37.36%	77,703 $111,000
Q3 2020 Nov 16, 2020	BUY	$1.6 - $3.0 $90,510 - $169,707	56,569 New	56,569 $102,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.